| Revenue | — | — | — |
| Precision oncology testing | 687.94a | 514.25a | 392.05a |
| Development services and other | 51.08a | 49.7a | 57.49a |
| Total revenue | 739.02a | 563.95a | 449.54a |
| Costs and operating expenses | — | — | — |
| Cost of precision oncology testing | -260.58a | -205.53a | -148.2a |
| Cost of development services and other | -29.22a | -21.52a | -8.13a |
| Research and development expense | -347.75a | -367.19a | -373.81a |
| Sales and marketing expense | -364.94a | -295.23a | -299.83a |
| General and administrative expense | -180.12a | -155.8a | -163.96a |
| Other operating expense | | -83.4a | |
| Total costs and operating expenses | -1,182.61a | -1,128.67a | -993.92a |
| Loss from operations | -443.59a | -564.73a | -544.38a |
| Interest income | 53.69a | 35.37a | 6.07a |
| Interest expense | -2.58a | -2.58a | -2.58a |
| Other income (expense), net | -42.61a | 53.17a | -12.78a |
| Fair value adjustments of noncontrolling interest liability | | | -99.79a |
| Loss before provision for income taxes | -435.09a | -478.76a | -653.45a |
| Provision for income taxes | -1.28a | -0.69a | -1.14a |
| Net loss | -436.37a | -479.45a | -654.59a |